Cargando…
A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9
The indolequinone EO9 demonstrated good preclinical activity but failed to show clinical efficacy against a range of tumours following intravenous drug administration. A significant factor in EO9's failure in the clinic has been attributed to its rapid pharmacokinetic elimination resulting in p...
Autores principales: | Choudry, G A, Stewart, P A Hamilton, Double, J A, Krul, M R L, Naylor, B, Flannigan, G M, Shah, T K, Brown, J E, Phillips, R M |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2001
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2375160/ https://www.ncbi.nlm.nih.gov/pubmed/11710826 http://dx.doi.org/10.1054/bjoc.2001.2056 |
Ejemplares similares
-
Update of the NAD(P)H:quinone oxidoreductase (NQO) gene family
por: Vasiliou, Vasilis, et al.
Publicado: (2006) -
NAD(P)H:Quinone Oxidoreductase 1 (NQO1) Localizes to the Mitotic Spindle in Human Cells
por: Siegel, David, et al.
Publicado: (2012) -
Aerobic Cytotoxicity of Aromatic N-Oxides: The Role of NAD(P)H:Quinone Oxidoreductase (NQO1)
por: Nemeikaitė-Čėnienė, Aušra, et al.
Publicado: (2020) -
NAD(P)H:Quinone Oxidoreductase 1 (NQO1) P187S Polymorphism and Prostate Cancer Risk in Caucasians
por: Stoehr, Christine G., et al.
Publicado: (2012) -
A polymorphism in NAD(P)H:quinone oxidoreductase (NQO1): relationship of a homozygous mutation at position 609 of the NQO1 cDNA to NQO1 activity.
por: Ross, D., et al.
Publicado: (1996)